Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2022 Jan 1;44(1):e213–e216. doi: 10.1097/MPH.0000000000002169

TABLE 2.

Propofol administration comparison by arm

Outcome Measure EMLA cream
N=75
Placebo
Cream
N=77
P-valuea
Total Propofol Dose (mg/kg)
Least Squares Mean (SE)
2.94 (0.25) 3.22 (0.19) 0.036
Additional Propofol Administered (Yes/No)
Mean Probability of Yes (SE)
0.49 (0.08) 0.69 (0.06) 0.001
Anesthesia Time (minutes)
Least Squares Mean (SE)
16.1 (1.0) 17.4 (0.9) 0.348
LP time (minutes)
Least Squares Mean (SE)
5.6 (0.5) 6.0 (0.7) 0.570
Time from Induction to end of LP
Least Squares Mean (SE)
7.9 (0.4) 8.4 (0.7) 0.501
Lowest BP Systolic (mm Hg)
Least Squares Mean (SE)
85.1 (1.8) 85.1 (2.0) 0.985
Lowest BP Diastolic (mm Hg)
Least Squares Mean (SE)
41.9 (1.3) 42.2 (1.2) 0.834
Lowest BP Percent Systolic (%)
Least Squares Mean (SE)
15.8 (3.5) 19.4 (4.2) 0.411
Lowest BP Percent Diastolic (%)
Least Squares Mean (SE)
16.3 (2.6) 18.9 (3.8) 0.415
Post-LP Headache (Yes/No)b
Mean Probability of Yes (SE)
0.19 (0.04) 0.29 (0.06) 0.094
Post-LP Back Pain (Yes/No)c
Mean Probability of Yes (SE)
0.21 (0.05) 0.25 (0.05) 0.426

EMLA, eutectic mixture of lidocaine and prilocaine; SE, standard error

a

p-value from Generalized Estimating Equation marginal model

b

for post-LP headache, N=68 for EMLA cream and N=73 for placebo

c

for post-LP back pain, N=69 for EMLA cream and N=74 for placebo